Stentys Joins Stent for Life Initiative to Expand Optimal Heart Attack Treatment across Europe

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS S.A. (STNT.PA), a medical technology company commercializing the world's first and only self-apposing stent to treat Acute Myocardial Infarction (AMI), announced today that it has joined the Stent for Life (SFL) Initiative as a key industry partner.

Back to news